Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | LPL | P06858 | 13/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293479 | 0.87 | RXRA (0.41) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL14552656 | 0.81 | LPL (0.40) | AAK1LPLLIPGHIF1ACA1 | |
| SCHEMBL130370 | 0.79 | CSF1R (0.43) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL1328329 | 0.79 | LPL (0.45) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL15788155 | 0.79 | CSF1R (0.43) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL29623476 | 0.79 | CSF1R (0.43) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL1293591 | 0.79 | AAK1 (0.48) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL8511356 | 0.79 | LPL (0.40) | AAK1LPLLIPGCA1CA2 | |
| SCHEMBL1643646 | 0.79 | HIF1A (0.42) | AAK1LPLLIPGHIF1ACA1 | |
| SCHEMBL1643648 | 0.78 | HIF1A (0.41) | AAK1LPLLIPGHIF1ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012069852-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF SPHINGOSINE KINASE | ALMAC DISCOVERY LIMITED (GB) | 2012-05-31 | — | — | WO | disclosed |